Literature DB >> 12382085

A second look at anorectal infections in cancer patients in a large cancer institute: the success of early intervention with antibiotics and surgery.

T Lehrnbecher1, D Marshall, C Gao, S J Chanock.   

Abstract

BACKGROUND: Infection of anorectal region represents a significant complication of anti-cancer therapy. Anorectal infection occurs in patients receiving aggressive chemotherapy. Untreated infection leads to substantial morbidity and in the past, mortality.
METHODS: 82 episodes of anorectal infection in 64 patients with malignant diseases occurring over 12 years at the National Cancer Institute (NCI) were retrospectively reviewed.
RESULTS: The overall incidence is comparable to the prior NCI experience despite a shift in patient population to a lower percentage of lymphoid/leukemic diagnoses (34% vs 77%). There were no deaths associated with anorectal infection in the 12 years reviewed compared to seven of 44 in the previous decade (p = 0.003). Antibiotic therapy alone was successful in managing 25/82. Only five episodes were treated with surgery alone compared to nearly 45% in the previous decade. There were no major surgical complications. Neutropenia was present in 43/82 episodes. 11 episodes were complicated by bacteremia, predominately with Staphylococcus non- aureus (n = 8). Wound cultures were performed in 36 episodes from 23 patients yielding 99 separate isolates. Gram-negative isolates were most common overall. Modification of antibiotic therapy with further anaerobic coverage was administered successfully in 39/77 episodes.
CONCLUSION: This study illustrates that anorectal infections in cancer patients can be successfully managed with antibiotic therapy and local care; surgery can be withheld unless there is evidence of progressive infection or substantial fluctuance and necrosis.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12382085     DOI: 10.1007/s15010-002-2197-8

Source DB:  PubMed          Journal:  Infection        ISSN: 0300-8126            Impact factor:   3.553


  6 in total

Review 1.  Wound care with antibacterial honey (Medihoney) in pediatric hematology-oncology.

Authors:  Arne Simon; Kai Sofka; Gertrud Wiszniewsky; Gisela Blaser; Udo Bode; Gudrun Fleischhack
Journal:  Support Care Cancer       Date:  2005-08-02       Impact factor: 3.603

Review 2.  Management of acute perianal sepsis in neutropenic patients with hematological malignancy.

Authors:  B Baker; M Al-Salman; F Daoud
Journal:  Tech Coloproctol       Date:  2013-11-26       Impact factor: 3.781

Review 3.  Surveillance of bloodstream infections in pediatric cancer centers - what have we learned and how do we move on?

Authors:  Arne Simon; Rhoikos Furtwängler; Norbert Graf; Hans Jürgen Laws; Sebastian Voigt; Brar Piening; Christine Geffers; Philipp Agyeman; Roland A Ammann
Journal:  GMS Hyg Infect Control       Date:  2016-05-12

4.  The Role of White Blood Cell Count in Perianal Pathologies: A Retrospective Analysis of Hematologic Malignancies.

Authors:  Bedrettin Orhan; Fahir Özkalemkaş; Vildan Özkocaman; Büşra Gürbüz; Tuba Ersal; İbrahim Ethem Pınar; Cumali Yalçin; Ömer Candar; Sinem Çubukçu; Tuba Güllü Koca; Rıdvan Ali
Journal:  Mediterr J Hematol Infect Dis       Date:  2022-07-01       Impact factor: 3.122

5.  Taurolidine-citrate lock solution (TauroLock) significantly reduces CVAD-associated grampositive infections in pediatric cancer patients.

Authors:  Arne Simon; Roland A Ammann; Gertrud Wiszniewsky; Udo Bode; Gudrun Fleischhack; Mette M Besuden
Journal:  BMC Infect Dis       Date:  2008-07-29       Impact factor: 3.090

6.  Anorectal Complications During Neutropenic Period in Patients with Hematologic Diseases.

Authors:  Soner Solmaz; Aslı Korur; Çiğdem Gereklioğlu; Süheyl Asma; Nurhilal Büyükkurt; Mutlu Kasar; Mahmut Yeral; İlknur Kozanoğlu; Can Boğa; Hakan Ozdoğu
Journal:  Mediterr J Hematol Infect Dis       Date:  2016-03-01       Impact factor: 2.576

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.